An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL-Reference-Cited by-同舟云学术

An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL

Published:2024-02 Issue:2 Volume:5 Page:101421
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Prinz Lars Fabian^ORCID,Riet Tobias,Neureuther Daniel Felix,Lennartz Simon,Chrobok Danuta,Hübbe Hanna,Uhl Gregor,Riet Nicole,Hofmann Petra,Hösel Marianna,Simon Adrian Georg,Tetenborg Luis,Segbers Paul,Shimono Joji,Gödel Philipp,Balke-Want Hyatt,Flümann Ruth,Knittel Gero,Reinhardt Hans Christian,Scheid Christoph,Büttner Reinhard,Chapuy Björn,Ullrich Roland Tillmann,Hallek Michael,Chmielewski Markus Martin

Funder

Deutsche Forschungsgemeinschaft

Stiftung Deutsche Krebshilfe

Publisher

Elsevier BV

Reference61 articles.

1. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma;Bachy;Nat. Med.,2022

2. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study;Schuster;Lancet Oncol.,2021

3. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1);Neelapu;Blood,2023

4. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study;Abramson;Lancet,2020

5. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy;Chong;N. Engl. J. Med.,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR-T cell technologies that interact with the tumour microenvironment in solid tumours;Expert Review of Clinical Immunology;2024-07-17